

Dirk Theile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9441429/publications.pdf>

Version: 2024-02-01

49
papers

762
citations

516710

16
h-index

552781

26
g-index

49
all docs

49
docs citations

49
times ranked

1266
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of drug transporters on cellular resistance towards saquinavir and darunavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2319-2328.	3.0	75
2	What, if all alerts were specific – Estimating the potential impact on drug interaction alert burden. <i>International Journal of Medical Informatics</i> , 2014, 83, 285-291.	3.3	75
3	Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. <i>Biochemical Pharmacology</i> , 2009, 78, 1366-1373.	4.4	57
4	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. <i>Biochemical Pharmacology</i> , 2013, 85, 265-273.	4.4	50
5	The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. <i>Cancer Letters</i> , 2016, 376, 165-172.	7.2	50
6	Clementine juice has the potential for drug interactions – In vitro comparison with grapefruit and mandarin juice. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 97, 247-256.	4.0	38
7	Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation. <i>Toxicology Letters</i> , 2014, 225, 43-47.	0.8	28
8	Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2011, 33, 959-968.	2.0	24
9	Effects of adrenergic mitotane on drug elimination pathways assessed in vitro. <i>Endocrine</i> , 2015, 49, 842-853.	2.3	23
10	Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e108908.	2.5	22
11	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 281-291.	2.3	22
12	Regulation of Biotransformation Systems and ABC Transporters by Benzimidazole in HepG2 Cells: Involvement of Pregnane X-Receptor. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1951.	3.0	20
13	Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro. <i>Pharmaceutics</i> , 2014, 6, 632-650.	4.5	18
14	Impact of enzalutamide and its main metabolite <i>N</i> -desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. <i>Biopharmaceutics and Drug Disposition</i> , 2017, 38, 517-525.	1.9	18
15	Association of Liver Stiffness with Hepatic Expression of Pharmacokinetically Important Genes in Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, E17-22.	2.4	17
16	Acquired ABC-transporter overexpression in cancer cells: transcriptional induction or Darwinian selection?. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 1621-1632.	3.0	17
17	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1.	3.2	17
18	Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1335-1343.	2.3	16

#	ARTICLE	IF	CITATIONS
19	Under-Reported Aspects of Platinum Drug Pharmacology. <i>Molecules</i> , 2017, 22, 382.	3.8	15
20	Methadone against cancer: Lost in translation. <i>International Journal of Cancer</i> , 2018, 143, 1840-1848.	5.1	14
21	In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteins. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 1518-1525.	2.4	13
22	Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1141-1150.	3.0	12
23	Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 51-58.	2.5	11
24	t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit. <i>Cellular Signalling</i> , 2017, 40, 53-61.	3.6	9
25	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 858-874.	2.4	9
26	Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2012, 385, 1025-1034.	3.0	8
27	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0193242.	2.5	8
28	Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 436-442.	3.4	7
29	Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs. <i>Toxicology Letters</i> , 2016, 242, 47-52.	0.8	6
30	Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2017, 390, 49-59.	3.0	6
31	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. <i>Oncology Letters</i> , 2017, 14, 3185-3192.	1.8	6
32	Regulation of PXR Function by Coactivator and Corepressor Proteins: Ligand Binding Is Just the Beginning. <i>Cells</i> , 2021, 10, 3137.	4.1	6
33	Obatoclox as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 1575-1584.	2.4	5
34	Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2016, 389, 1091-1101.	3.0	5
35	Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 71-79.	2.3	5
36	In vitro evidence suggesting that the toll-like receptor 7 and 8 agonist resiquimod (R-848) unlikely affects drug levels of co-administered compounds. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 162, 105826.	4.0	5

#	ARTICLE	IF	CITATIONS
37	Desmethyl bosentan displays a similar inÂvitro interaction profile as bosentan. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 30, 80-86.	2.6	4
38	Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays. <i>Analytical Biochemistry</i> , 2016, 509, 124-129.	2.4	4
39	Reporter cell assay-based functional quantification of TNF-Î±-antagonists in serum â€œ a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020, 596, 113646.	2.4	3
40	Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes. <i>Pharmaceutics</i> , 2021, 13, 808.	4.5	3
41	How to avoid misinterpretation of dual reporter gene assay data affected by cell damage. <i>Archives of Toxicology</i> , 2022, 96, 2501-2510.	4.2	3
42	Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. <i>Analytical Biochemistry</i> , 2015, 471, 23-25.	2.4	2
43	Pharmacodynamic monitoring using biomarkers to individualize pharmacotherapy. <i>Biomarkers in Medicine</i> , 2019, 13, 393-408.	1.4	2
44	A nuclear factor kappa B reporter cell line used to evaluate ex vivo the net inflammatory effect of plasma samples from patients with rheumatoid arthritis, psoriasis, or COVID-19. <i>Cytokine</i> , 2021, 138, 155399.	3.2	2
45	Deceptive argumentation against diagnostic microdosing of anticancer drugs. <i>International Journal of Cancer</i> , 2014, 135, 1753-1754.	5.1	1
46	Given the Data of Hommers and Colleagues, Valproic Acid Is Not an Unequivocal Inducer of Clozapine Metabolism. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 419-420.	1.4	1
47	Comment on â€œSweat but no gainâ€• Inhibiting proliferation of multidrug resistant cancer cells with â€œErsatzdrogesâ€• <i>International Journal of Cancer</i> , 2015, 136, 2241-2242.	5.1	0
48	Bosentan enhances <i>inÂvitro</i> bortezomib's antiâ€œproliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade. <i>British Journal of Haematology</i> , 2019, 184, 1052-1055.	2.5	0
49	Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 461-466.	3.0	0